|
Feb 24
|
Travere Therapeutics to Participate at Upcoming Investor Conferences
|
|
Feb 22
|
Travere Therapeutics price target raised to $30 from $24 at TD Cowen
|
|
Feb 22
|
Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 20
|
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 14
|
Travere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling Recently
|
|
Feb 13
|
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 13
|
Travere Therapeutics price target raised to $32 from $27 at Scotiabank
|
|
Feb 11
|
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
|
|
Jan 1
|
High Growth Tech Stocks in the United States to Watch
|
|
Oct 9
|
Travere Therapeutics Inc (TVTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
|
|
Oct 9
|
Travere Therapeutics, Inc. (TVTX) Increases R&D Investments Amidst Rising Product Sales
|
|
Oct 7
|
Exploring 3 High Growth Tech Stocks in the United States
|
|
Sep 5
|
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
|
|
Sep 4
|
High Growth Tech Stocks To Watch In September 2024
|
|
Jul 25
|
Travere Therapeutics to Report Second Quarter 2024 Financial Results
|
|
Jun 18
|
Shareholders in Travere Therapeutics (NASDAQ:TVTX) are in the red if they invested five years ago
|
|
May 9
|
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
|
|
May 8
|
Travere Therapeutics to Present at Upcoming Investor Conferences
|
|
May 8
|
Loss-Making Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected To Breakeven In The Medium-Term
|
|
May 7
|
Travere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...
|